ArticleAlzheimer's research & therapy2025
The biomarker and clinical changes across the Alzheimer's continuum study (BCAS): rationale, design, and baseline characteristics of the first 1,013 participants.
Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis.Annals of clinical and translational neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) is the leading cause of dementia in China, but deeply phenotyped clinical cohorts remain limited. The Biomarker and Clinical changes across the Alzheimer's continuum Study (BCAS) was established at the First Affiliated Hospital, Zhejiang University School of Medicine to capture biological and clinical changes across the AD spectrum.
methodsBCAS is an ongoing, longitudinal memory clinic-based cohort initiated in 2016 in Zhejiang, one of China's most economically vigorous and rapidly aging regions. Individuals aged ≥ 40 years with cognitive concerns are recruited and undergo standardized clinical evaluation, comprehensive neuropsychological testing, biospecimen collection, and multimodal neuroimaging including MRI and amyloid and tau PET in subsets. Participants are followed every 1-2 years with repeat assessments. This paper reports baseline characteristics and preliminary findings from the first 1,013 participants enrolled up to January 2025.
resultsParticipants had a mean age of 66.5 years (SD 9.6), with 49.8% women and an average of 9.7 years of education. Hypertension (41.4%), diabetes (14.6%), and hypercholesterolemia (12.0%) were the most prevalent comorbidities. The mean MoCA score was 19.2 (SD 6.1). Mean cognitive scores showed gradient decline across diagnostic groups from cognitively unimpaired, mild cognitive impairment to dementia, consistent with expected disease severity. Tau PET positivity showed a numerically larger cognitive z-score difference (-0.973 for T + vs. T-) compared with amyloid PET positivity (-0.530 for A + vs. A-). Among risk factors, higher age and diabetes were linked to lower scores, whereas higher education, tea consumption, and higher BMI were associated with better cognitive performance.
conclusionsThe BCAS served as a biomarker-rich and multimodal resource to study the clinical and biological progression of AD in China. Preliminary analyses demonstrate expected associations and support the data quality. BCAS will act as a platform for biomarker validation and precision approaches to AD diagnosis and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.